Tetsuro Tamaki

Muscle Physiology & Cell Biology Unit, Department of Regenerative Medicine, Division of Basic Clinical Science, Tokai University School of Medicine, Isehara, Japan

Bridging long gap peripheral nerve injury using skeletal muscle-derived multipotent stem cells

Tetsuro Tamaki

Muscle Physiology & Cell Biology Unit, Department of Regenerative Medicine, Division of Basic Clinical Science, Tokai University School of Medicine, Isehara, Japan

Long gap peripheral nerve injuries usually reulting in life-changing problems for patients. Skeletal muscle derived-multipotent stem cells (Sk-MSCs) can differentiate into Schwann and perineurial/endoneurial cells, vascular relating pericytes, and endothelial and smooth muscle cells in the damaged peripheral nerve niche. Application of the Sk-MSCs in the bridging conduit for repairing long nerve gap injury resulted favorable axonal regeneration, which showing superior effects than gold standard therapy--healthy nerve autograft. This means that it does not need to sacri fi ce of healthy nerves or loss of related functions for repairing peripheral nerve injury.

peripheral nerve support cells, Schwann cells, perineurium, endoneurium, cytokine, paracrine effect, blood vessel formation

Funding: This work was supported by a 2013 Tokai University School of Medicine, Project Research Grant.

Tamaki T. Bridging long gap peripheral nerve injury using skeletal muscle-derived multipotent stem cells. Neural Regen Res. 2014;9(14)：1333-1336.

Introduction

Peripheral nerve injury is frequently caused by various traumatic injuries. Unavoidable tissue resections following surgical tumor excision can also lead to nerve damage. Although the peripheral nervous system has the ability to regenerate axons following injury, when nerve gaps are larger than 1-2 cm, bridging strategies are required for repair. In such cases, autologous nerve grafts have been used as the gold standard (Deumens et al., 2010; Pfister et al., 2011), although this requires the sacrifice of healthy nerves. However, there are limited numbers of suitable sites for harvesting nerve grafts, because of the adverse effects to donor sites, such as the loss of motor and sensory function.

Development of nerve bridging conduit

In order to overcome these issues, scaffold bridging materials that may be synthetic, absorbable or non-absorbable have been studied vigorously. Through these studies, several criteria were suggested to be necessary for better results, as follows: 1) the bridging conduit is necessary to maintain adequate mechanical support of separated nerve ends, in addition to preventing the diffusion of neurotrophic and neurotropic factors secreted by transected stumps (Deumens et al., 2010); 2) nerve scaffolds should be biocompatible in order to eliminate undesirable in fl uences on neural cells/tissues, such as immune rejection (Avitable et al., 2001); 3) it should be degradable and/or absorbable in the appropriate duration in vivo (de Ruiter et al., 2009); 4) it must have suf fi cient permeability for nutrient and gas exchange (She et al., 2008); and 5) it must have a biomechanical fl exibility to allow bending at the graft site, without kinking the transected nerve stumps (Gu et al., 2011). For longer nerve gap injuries, it is likely that scaffold structure will be another important factor. Scaffolds with a single hollow lumen represent the basic structure, but this has been re fi ned using various biosynthetic materials in order to mimic the nerve-graft structure and to facilitate axonal re-extension. The multi-luminal substructure (de Ruiter et al., 2008b) and the filament-filled structure (Bunting et al., 2005; Cai et al., 2005; Hu et al., 2008) are typical cases; the former shows no signi fi cant bene fi t, but the latter shows improved nerve regeneration, as compared to the single lumen scaffold. Intraluminal surface coating with extracellular matrix (ECM) components, such as laminin, fi bronectin and collagen, has been also attempted to promote active axonal re-growth. First, this was attempted using a single hollow conduit, and several positive effects were obtained (Kauppila et al., 1993; Whitworth et al.,1995). In this regard, the use of conduits of biological origin, such as acellular conduits, which have preserved ECM components, but are decellularized and immunosuppressed, was another approach (Frerichs et al., 2002; Hudson et al., 2004a). However, use of this hollow-type conduit shows non-significant effects on nerve regeneration across long gaps (P fi ster et al., 2011). In contrast, conduits including laminin-coated collagen fi bers were able to support the regeneration of long sciatic nerve gaps of over 80 mm in dogs (Matsumoto et al., 2000). At this point, the fi lament- fi lled conduit with laminin coating is likely to be the best alternative method. Importantly, these efforts have been performed to expect alternative effects oflaminin-coated fibers in the conduit, similar to the basal lamina sheet in the individual endoneurium of the healthy nerve fibers. Laminin coating may exert supportive effects for the migration, proliferation and orientation of preserved Schwann cells, similarly to formation of Bands of Bungner, which normally occurs in the case of axonotmesis (Deumens et al., 2010). Furthermore, application of growth factors into the conduit is another method to mimic native conditions. For example, supply of several factors into the conduit, such as nerve growth factor (NGF), brain-derived neurotrophic factor (BDNF), glial cell line-derived neurotrophic factor (GDNF), ciliary neurotrophic factor (CNTF), basic fibroblast growth factor (bFGF) and insulin-like growth factor-1 (IGF-1), has also been performed, and favorable effects on axonal growth and nerve regeneration have been con fi rmed (Rich et al., 1989; Nachemson et al., 1990; Fine et al., 2002; Timmer et al., 2003; Lewin et al., 2009).

Combination with cell transplantation

All of the applications described above were based on the notion of simulating the healthy nerve graft condition. In this regard, transplantation of Schwann cells with the conduit is considered to be the best method as the alternative for nerve grafting. Acellular conduits have thus been used with several cell sources, including Schwann cells and/or Schwann-like cells induced from cultivated bone morrow stromal cells (Dezawa et al., 2005), olfactory ensheathing cells (Radtke et al., 2011) and adipose tissue-derived cells (Kingham et al., 2007), but it is unlikely that these cells would match or exceed the performance of auto nerve grafts. Although Schwann cells play a central role in peripheral nerve regeneration, the formation of endoneurium and/or perineurium by endoneurial fi broblasts and perineurial cells is also important because of their protective role in axons with Schwann cells and myelin sheath. In particular, the perineurium plays an important role in preventing the passage of large molecules from the epineurium into perineurial fascicles, which is also known as the “blood-nerve-barrier” system (Weerasuriya and Mizisin, 2011). Furthermore, reconstitution of vascular networks is also an inevitable factor in tissue reconstruction. In this regard, cell sources that can give rise to Schwann cells and cells associated with the formation of perineurium/endoneurium and blood vessels are considered to be the best source for peripheral nerve regeneration.

Comprehensive regeneration with all nerve support cells/tissues

Recently, we reported preferential and comprehensive reconstitution of severely damaged sciatic nerve using 7-day cultivated murine skeletal muscle-derived multipotent stem cells (Sk-MSCs; Tamaki et al., 2014). In this treatment, engrafted donor cells preferentially differentiated into Schwann cells and perineurial/endoneurial cells, and formed myelin sheath and perineurium/endoneurium, encircling the regenerated axons. Donor cell-derived perineurium also had tight-junctions, which play a key role in the “blood-nerve-barrier”system; thus, suggesting functional reconstitution. Stem cells showing suitable multipotency to cover all peripheral nerve support cells in damaged nerve-speci fi c niche have not been reported previously, although cultivated bone morrow stromal cells (MBCSs; Dezawa et al., 2005), olfactory ensheathing cells (Radtke et al., 2011) and adipose tissue-derived cells (Kingham et al., 2007) have been studied mainly expecting the differentiation of transplanted cells into Schwann cells. We directly compared the contribution to damaged nerve reconstitution among cultivated Sk-MSCs and BMSCs, and freshly isolated cells derived from damaged sciatic nerve (SNDC-D) (Tamaki et al., 2014). The results showed that Sk-MSCs have a signi fi cantly greater engraftment ratio when compared with the other two groups, and the values in the latter two groups were similar. In addition, there was no de fi nitive formation of peripheral nerve supporting cells or incorporation into blood vessels in BMSC transplantation, whereas Sk-MSCs and SNDC-D showed typical differentiation into all support cells. In addition, engrafted Sk-MSCs contributed to increased vascular formation, which is favorable for blood supply and waste product excretion. Facilitation of blood vessel formation in Sk-MSCs was also con fi rmed in damaged skeletal muscle (Tamaki et al., 2005; 2007b; 2013) and urethra (Hoshi et al., 2008), as well as in and around the bladder wall (Nitta et al., 2010; Soeda et al., 2013). This trend appears to be typical of Sk-MSC transplantation. Expression of key neurotrophic and nerve/vascular growth factor mRNAs was also con fi rmed; in particular, NGF (Rich et al., 1989), BDNF (Lewin et al., 2009), GDNF (Fine et al., 2002), Galectin-1 (Horie et al., 1999), Ninjurin (Araki and Milbrandt, 1996), CNTF (Dubovy et al., 2011), LIF (Wang et al., 2009), Sox10 (Bremer et al., 2011; Britsch et al., 2001; Finzsch et al., 2010), bFGF (Timmer et al., 2003) and IGF-1 (Nachemson et al., 1990) are important for nerve regeneration, while VGEF (Ferrara, 2004) and HGF (Schroder et al., 2011) are important for blood vessels. Expression of these factors was retained for at least 4 weeks after transplantation. Some of these are redundant and/or primarily involved in the recipient nerve regeneration process (Campbell, 2008); however, sufficient expression of these factors in the damaged/transplantation site may induce paracrine effects on both recipient and donor cells as an adjuvant for nerve regeneration. Using Sk-MSCs, we examined the therapeutic capacity in a long transected nerve gap on the mouse sciatic nerve via an acellular conduit (1.5-2.0 × 106cells/ nerve), and demonstrated 94% reconstitution of the number of axons, 60% recovery of myelin, and a 9.1-fold increase in blood vessels through the conduit (Tamaki et al., 2014). Features and immunohistochemical properties of regenerated nerve at 8 weeks after bridging with Sk-MSCs transplantation are shown in Figure 1. Thick GFP+tissues were evident throughout the conduit (Figure 1A), and a large number of GFP+multi-luminal substructures, such as perineurium/ endoneurium, were also apparent in histological sections (Figure 1B and C). Importantly, regenerated axons in the conduit were encircled by engrafted GFP+perineurium/ endoneurium (Figure 1B), having myelination (Figure 1C), thus suggesting that regenerating axons extended along the endoneurial/perineurial substructures with supporting Schwann cells. The bridging acellular conduit also includes a large number of blood vessels (Figure D); thus, favorableblood supply and waste product excretion are expected. These relationships between GFP+tissues and regenerated axons were con fi rmed in longitudinal sections (Figure 1E), and GFP+multi-luminal substructures also possessed the basal lamina sheath (Figure 1F and G). These results clearly indicated that our nerve treatment method using the Sk-MSCs with acellular conduits meet all of the above criteria, making it useful for nerve regeneration. In addition, we also demonstrated the greater therapeutic potential of Sk-MSC treatment as compared to case of healthy nerve grafts using the same mouse model (Tamaki et al., 2014).

Figure 1 Typical structure of engrafted GFP+skeletal muscle-derived multipotent stem cells (Sk-MSCs) in acellular bridging conduit at 8 weeks after transplantation.

In conclusion, skeletal muscle is the largest organ in the body, comprising approximately 40-50% of total body mass, and presumably allowing donor cells to be obtained with relative ease and safety. Therefore, Sk-MSCs represent a novel/suitable alternative cell source for healthy nerve autografts. Skeletal muscle-derived stem cells have been used by many researchers for various purposes; however, our isolation method of Sk-MSCs differs from others (Tamaki et al., 2002; 2010), and this is potentially crucial to our results after transplantation (Tamaki et al., 2005, 2007a,b).

Future perspectives

In future research, the potential of human skeletal muscle-derived cells needs to be clari fi ed. We are currently investigating the optimal isolation, fractionation and expansion culture conditions for human cells in order to maximize the nerve regeneration potential. In vivo evidence of the differentiation and reconstruction capacities of human Sk-MSCs is also important. In addition, suitable combinations of conduit materials remain to be clari fi ed. We used the acellular conduit from the wild-type mice esophageal submucous membrane (mainly longitudinal muscle layer) separated after 3 days of 70% ethanol dehydration. In the human case, use of an appropriate size vein may be a candidate cellular or acellular conduit. However, from the viewpoint of minimizing invasiveness, biosynthetic tubes that are a good match for Sk-MSCs treatment need to be identi fi ed. Application of Sk-MSC treatment for the total regeneration of multi-branched nerve transections may also be useful in the case of surgical nerve damage.

Araki T, Milbrandt J (1996) Ninjurin, a novel adhesion molecule, is induced by nerve injury and promotes axonal growth. Neuron 17:353-361.

Avitabile, T, Marano F, Castiglione F, Bucolo C, Cro M, Ambrosio L, Ferrauto C, Reibaldi A (2001) Biocompatibility and biodegradation of intravitreal hyaluronan implants in rabbits. Biomaterials 22;195-200.

Bremer M, Frob F, Kichko T, Reeh P, Tamm ER, Suter U, Wegner M (2011) Sox10 is required for Schwann-cell homeostasis and myelin maintenance in the adult peripheral nerve. Glia 59:1022-1032.

Britsch S, Goerich DE, Riethmacher D, Peirano RI, Rossner M, Nave KA, Birchmeier C, Wegner M (2001) The transcription factor Sox10 is a key regulator of peripheral glial development. Genes Dev 15:66-78.

Bunting S, Di Silvio L, Deb S, Hall S (2005) Bioresorbable glass fi bres facilitate peripheral nerve regeneration. J Hand Surg Br 30;242-247.

Cai J, Peng X, Nelson KD, Eberhart R, Smith GM (2005) Permeable guidance channels containing micro fi lament scaffolds enhance axon growth and maturation. J Biomed Mater Res A 75:374-386.

Campbell WW (2008) Evaluation and management of peripheral nerve injury. Clin Neurophysiol 119:1951-1965.

de Ruiter GC, Spinner RJ, Malessy MJA, Moore MJ, Sorenson EJ, Currier BL, Yaszemski MJ, Windebank AJ (2008) Accuracy of motor axon regeneration across autograft, single-lumen, and multichannel poly(-lactic-co-glycolic acid) nerve tubes. Neurosurgery 63;144-153.

de Ruiter GC, Spinner RJ, Yaszemski MJ, Windebank AJ, Malessy MJ (2009) Nerve tubes for peripheral nerve repair. Neurosurg Clin N Am 20;91-105 vii.

Deumens R, Bozkurt A, Meek MF, Marcus MA, Joosten EA, Weis J, Brook G.A (2010) Repairing injured peripheral nerves: Bridging the gap. Prog Neurobiol 92:245-276.

Dezawa M, Ishikawa H, Hoshino M, Itokazu Y, Nabeshima Y (2005) Potential of bone marrow stromal cells in applications for neuro-degenerative, neuro-traumatic and muscle degenerative diseases. Curr Neuropharmacol 3:257-266.

Dubovy P, Raska O, Klusakova I, Stejskal L, Celakovsky P, Haninec P (2011) Ciliary neurotrophic factor promotes motor reinnervation of the musculocutaneous nerve in an experimental model of end-toside neurorrhaphy. BMC Neurosci 12:58.

Ferrara N (2004) Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev 25:581-611.

Fine EG, Decosterd I, Papaloı¨zos M, Zurn AD, Aebischer P (2002) GDNF and NGF released by synthetic guidance channels support sciatic nerve regeneration across a long gap. Eur J Neurosci 15;589-601.

Finzsch M, Schreiner S, Kichko T, Reeh P, Tamm ER, Bosl MR, Meijer D, Wegner M (2010) Sox10 is required for Schwann cell identity and progression beyond the immature Schwann cell stage. J Cell Biol 189:701-712.

Frerichs O, Fansa H, Schicht C, Wolf G, Schneider W, Keilhoff G (2002) Reconstruction of peripheral nerves using acellular nerve grafts with implanted cultured Schwann cells. Microsurgery 22;311-315.

Gu X, Ding F, Yang Y, Liu J (2011) Construction of tissue engineered nerve grafts and their application in peripheral nerve regeneration. Prog Neurobiol 93:204-30.

Horie H, Inagaki Y, Sohma Y, Nozawa R, Okawa K, Hasegawa M, Muramatsu N, Kawano H, Horie M, Koyama H, Sakai I, Takeshita K, Kowada Y, Takano M, Kadoya T (1999) Galectin-1 regulates initial axonal growth in peripheral nerves after axotomy. J Neurosci 19:9964-9974. Hoshi A, Tamaki T, Tono K, Okada Y, Akatsuka A, Usui Y, Terachi T (2008) Reconstruction of radical prostatectomy-induced urethral damage using skeletal muscle-derived multipotent stem cells. Transplantation 85:1617-1624.

Hu W, Gu J, Deng A, Gu X (2008) Polyglycolic acid filaments guide Schwann cell migration in vitro and in vivo. Biotechnol Lett 30;1937-1942.

Hudson TW, Liu SY, Schmidt CE (2004) Engineering an improved acellular nerve graft via optimized chemical processing. Tissue Eng 10;1346-1358.

Kauppila T, Jyvasjarvi E, Huopaniemi T, Hujanen E, Liesi P (1993) A laminin graft replaces neurorrhaphy in the restorative surgery of the rat sciatic nerve. Exp Neurol 123:181-191.

Kingham PJ, Kalbermatten DF, Mahay D, Armstrong SJ, Wiberg M, Terenghi G (2007) Adipose-derived stem cells differentiate into a Schwann cell phenotype and promote neurite outgrowth in vitro. Exp Neurol 207:267-274.

Lewin SL, Utley DS, Cheng ET, Verity AN, Terris DJ (2009) Simultaneous treatment with BDNF and CNTF after peripheral nerve transection and repair enhances rate of functional recovery compared with BDNF treatment alone. Laryngoscope 107;992-999.

Matsumoto K, Ohnishi K, Sekine T, Ueda H, Yamamoto Y, Kiyotani T, Nakamura T, Endo K, and Shimizu Y (2000) Use of a newly developed arti fi cial nerve conduit to assist peripheral nerve regeneration across a long gap in dogs. ASAIO J 46: 415-420.

Nachemson AK, Lundborg G, Hansson HA (1990) Insulin-like growth factor I promotes nerve regeneration: an experimental study on rat sciatic nerve. Growth Factors 3:309-314.

Nitta M, Tamaki T, Tono K, Okada Y, Masuda M, Akatsuka A, Hoshi A, Usui Y, Terachi T (2010) Reconstitution of experimental neurogenic bladder dysfunction using skeletal muscle-derived multipotent stem cells. Transplantation 89:1043-1049.

P fi ster BJ, Gordon T, Loverde JR, Kochar AS, Mackinnon SE, Cullen DK (2011) Biomedical engineering strategies for peripheral nerve repair: surgical applications, state of the art, and future challenges. Crit Rev Biomed Eng 39:81-124.

Radtke C, Wewetzer K, Reimers K, Vogt PM (2011) Transplantation of olfactory ensheathing cells as adjunct cell therapy for peripheral nerve injury. Cell Transplant 20:145-152.

Rich KM, Alexander TD, Pryor JC, Hollowell JP (1989) Nerve growth factor enhances regeneration through silicone chambers. Exp Neurol 105:162-170.

Schroder K, Schutz S, Schloffel I, Batz S, Takac I, Weissmann N, Michaelis UR, Koyanagi M, Brandes RP (2011) Hepatocyte growth factor induces a proangiogenic phenotype and mobilizes endothelial progenitor cells by activating Nox2. Antioxid Redox Signal 15:915-923.

She ZD, Zhang BF, Jin CR, Feng QL, Xu YX (2008) Preparation and in vitro degradation of porous three-dimensional silk fi broin/chitosan scaffold. Polymer Degrad Stab 93:1316-1322.

Soeda S, Tamaki T, Hashimoto H, Saito K, Sakai A, Nakajima N, Nakazato K, Masuda M, Terachi T (2013) Functional nerve-vascular reconstitution of the bladder-wall; application of patch transplantation of skeletal muscle-derived multipotent stem cell sheet-pellets. J Stem Cell Res Ther 3:142.

Tamaki T, Akatsuka A, Ando K, Nakamura Y, Matsuzawa H, Hotta T, Roy RR, Edgerton VR (2002) Identi fi cation of myogenic-endothelial progenitor cells in the interstitial spaces of skeletal muscle. J Cell Biol 157:571-577.

Tamaki T, Uchiyama Y, Okada Y, Ishikawa T, Sato M, Akatsuka A, Asahara T (2005) Functional recovery of damaged skeletal muscle through synchronized vasculogenesis, myogenesis, and neurogenesis by muscle-derived stem cells. Circulation 112:2857-2866.

Tamaki T, Okada Y, Uchiyama Y, Tono K, Masuda M, Wada M, Hoshi A, Ishikawa T, Akatsuka A (2007a) Clonal multipotency of skeletal muscle-derived stem cells between mesodermal and ectodermal lineage. Stem Cells 25:2283-2290.

Tamaki T, Okada Y, Uchiyama Y, Tono K, Masuda M, Wada M, Hoshi A, Akatsuka A (2007b) Synchronized reconstitution of muscle fi bers, peripheral nerves and blood vessels by murine skeletal muscle-derived CD34(-)/45 (-) cells. Histochem Cell Biol 128:349-360.

Tamaki T, Uchiyama Y, Akatsuka A (2010) Plasticity and physiological role of stem cells derived from skeletal muscle interstitium: contribution to muscle fi ber hyperplasia and therapeutic use. Curr Pharm Des 16:956-967.

Tamaki T, Soeda S, Hashimoto H, Saito K, Sakai A, Nakajima N, Masuda M, Fukunishi N, Uchiyama Y, Terachi T, Mochida J (2013) 3D reconstitution of nerve-blood vessel networks using skeletal muscle-derived multipotent stem cell sheet pellets. Regen Med 8:437-451.

Tamaki T, Hirata M, Soeda S, Nakajima N, Saito K, Nakazato K, Okada Y, Hashimoto H, Uchiyama Y, Mochida J (2014) Preferential and comprehensive reconstitution of severely damaged sciatic nerve using murine skeletal muscle-derived multipotent stem cells. PLoS One 9:e91257.

Timmer M, Robben S, Muller-Ostermeyer F, Nikkhah G, Grothe C (2003) Axonal regeneration across long gaps in silicone chambers fi lled with Schwann cells overexpressing high molecular weight FGF-2. Cell Transplant 12:265-277.

Wang L, Lee HK, Seo IA, Shin YK, Lee KY, Park HT (2009) Cell type-speci fi c STAT3 activation by gp130-related cytokines in the peripheral nerves. Neuroreport 20:663-668.

Weerasuriya A, Mizisin AP (2011) The blood-nerve barrier: structure and functional signi fi cance. Methods Mol Biol 686:149-173.

Whitworth IH, Brown RA, Dore C, Green CJ, Terenghi G (1995) Orientated mats of fi bronectin as a conduit material for use in peripheral nerve repair. J Hand Surg Br 20:429-436.

10.4103/1673-5374.137582

Tetsuro Tamaki, Ph.D., Muscle Physiology and Cell Biology Unit, Department of

Regenerative Medicine, Division of Basic Clinical Science, Tokai University School of Medicine, 143-Shimokasuya, Isehara, Kanagawa 259-1143, Japan,tamaki@is.icc.u-tokai.ac.jp.

http://www.nrronline.org/

Accepted: 2014-07-04